STOCK TITAN
  1. Home
  2. News
  3. HSDT

Helius Med Technologies Inc - HSDT STOCK NEWS

Welcome to our dedicated page for Helius Med Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Med Technologies stock.

Helius Medical Technologies Inc (NASDAQ: HSDT) is a pioneering neurotechnology company focused on non-invasive therapies for neurological deficits. This page provides investors and healthcare professionals with essential updates on HSDT's progress, including regulatory milestones, clinical trial results, and strategic initiatives.

Discover the latest developments surrounding the Portable Neuromodulation Stimulator (PoNS), partnerships with medical institutions, and financial performance updates. Our curated news collection ensures you stay informed about HSDT's advancements in neuroplasticity-based treatments for conditions like multiple sclerosis and traumatic brain injury.

This resource aggregates official press releases, earnings reports, and market-related announcements. Key coverage areas: FDA regulatory updates, clinical study outcomes, executive leadership changes, and technology licensing agreements. Bookmark this page for streamlined access to material information impacting HSDT's position in the medical device sector.

News

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Rhea-AI Summary
Helius Medical Technologies, Inc. announces FDA interaction and clinical program optimization for PoNS Therapy in stroke patients. The company aims to evaluate non-invasive neuromodulation for gait and balance deficits, targeting regulatory submission and marketing authorization by 2025. Real-world evidence demonstrates significant improvement in gait and balance, positioning the company for potential breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
none
-
News

Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS

Rhea-AI Summary
Helius Medical Technologies, Inc. expands its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections Meeting to showcase its Portable Neuromodulation Stimulator (PoNS®) and highlight the role of physical therapists in using the therapy to improve gait in people with multiple sclerosis (MS). PoNS-trained physical therapists are now present in 10 states across the US, including those with the highest MS prevalence such as New York, California, and Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
News

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) expands registrational program for PoNS Therapy™ with the addition of Brooks Rehabilitation Hospital, bringing the total number of patients to 100. The study focuses on evaluating cranial-nerve non-invasive neuromodulation for gait/balance deficits in chronic stroke survivors, with the goal of achieving U.S. authorization under PoNS’s breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
News

Helius Medical Technologies to Present at NobleCon19 Annual Conference

Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) to present at NobleCon 19th Annual Emerging Growth Equity Conference. President and CEO Dane Andreeff to discuss novel therapeutic neuromodulation approach for balance and gait deficits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
News

Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announces Q3 2023 results, with $143 thousand in revenue, a decrease from Q3 2022, and operating cash burn of $2.5 million. The company extended its cash runway into Q2 2024, and received UPC numbers for the PoNS system and mouthpiece, allowing for dual paths of reimbursement. A letter of intent from the Québec Ministry of Health and Social Services for the purchase of up to 30 PoNS systems was also received.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
earnings
-
News

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work

Rhea-AI Summary
Helius Medical Technologies has announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator (PoNS) can significantly improve return-to-work outcomes for patients suffering from traumatic brain injury (TBI). The study, co-sponsored by Pacific Blue Cross and HealthTech Connex, showed that 56% of participants who were previously unable to work due to TBI returned to their prior occupations after 14 weeks of PoNS Therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
News

Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024

Rhea-AI Summary
Helius Medical Technologies, Inc. expects to report Q3 revenues between $140,000 and $150,000 due to the conclusion of the Patient Therapy Access Program. They also anticipate having approximately $7.0 million in cash and extending their cash runway into Q2 2024. The company will release its Q3 2023 financial results on November 9, 2023, and will host a conference call to discuss the results and provide an update on their progress and plans for the U.S. commercialization of PoNS®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
earnings
-
News

Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices

Rhea-AI Summary
Helius Medical Technologies receives letter of intent from Québec Ministry of Health and Social Services for purchase of 30 PoNS devices
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
News

Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences

Rhea-AI Summary
Helius Medical Technologies CFO to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
News

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

Rhea-AI Summary
Helius Medical Technologies has announced that its PoNS system and mouthpiece have been assigned UPC numbers by Wolters Kluwer Health, allowing the company to pursue reimbursement through both pharmacy and DME/HCPCS pathways. The PoNS system has a direct price of $25,700 and the mouthpiece has a direct price of $7,900. This development is seen as a gamechanger for Helius, potentially expediting negotiations with third-party payers and providing dual paths for potential reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Stock HSDT logo
Helius Med Technologies Inc

Nasdaq:HSDT

HSDT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HSDT Stock Data

1.56M
6.11M
0.53%
6.63%
0.34%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEWTOWN